Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW1809 vs DW1809-1 PK study in healthy volunteers
NCT05214677Phase 1Completed
- Sponsor
- Daewon Pharm
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pelubiprofen in osteoarthritis (OA), rheumatoid arthritis (RA), back pain and 1 more (2 arms), sponsored by Daewon Pharm. Primary endpoints: Peak Plasma Concentration at 8 hours and Area under the plasma concentration versus time curve at 8 hours. Started Aug 2020; status: completed.
02
Drugs
pelubiprofen
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)back painacute upper respiratory tract infection (URI)
Beyond the preview
Go deeper on NCT05214677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214677.